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An Interchangeable Role for Kainate and Metabotropic
Glutamate Receptors in the Induction of Rat Hippocampal
Mossy Fiber Long-Term Potentiation In Vivo
James L. Wallis, Mark W. Irvine, David E. Jane, David Lodge,
Graham L. Collingridge,* and Zuner A. Bortolotto*
ABSTRACT: The roles of both kainate receptors (KARs) and metabo-
tropic glutamate receptors (mGluRs) in mossy fiber long-term potentia-
tion (MF-LTP) have been extensively studied in hippocampal brain slices,
but the findings are controversial. In this study, we have addressed the
roles of both mGluRs and KARs in MF-LTP in anesthetized rats. We found
that MF-LTP could be induced in the presence of either GluK1-selective
KAR antagonists or group I mGluR antagonists. However, LTP was inhib-
ited when the group I mGluRs and the GluK1-KARs were simultaneously
inhibited. Either mGlu1 or mGlu5 receptor activation is sufficient to
induce this form of LTP as selective inhibition of either subtype alone,
together with the inhibition of KARs, did not inhibit MF-LTP. These data
suggest that mGlu1 receptors, mGlu5 receptors, and GluK1-KARs are all
engaged during high-frequency stimulation, and that the activation of any
one of these receptors alone is sufficient for the induction of MF-LTP in
vivo. VC 2015 The Authors Hippocampus Published by Wiley Periodicals, Inc.
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INTRODUCTION
Long-term potentiation (LTP) is widely considered to provide a good
model system for understanding the synaptic processes involved in infor-
mation storage in the central nervous system. Most forms of LTP are
induced by the synaptic activation of N-methyl-D-aspartate receptors
(NMDARs) and involve both pre- and postsynaptic modes of expression
(Bliss and Collingridge, 1993, 2013). There are, however, also
NMDAR-independent forms of LTP as first identified (Harris and
Cotman, 1986), and most extensively characterized, at the mossy fiber
synapse in the hippocampus (Nicoll and Schmitz, 2005; Jane et al.,
2009).
The role of glutamate receptors in the induction of
mossy fiber LTP (MF-LTP) is controversial. Initial
studies suggested that MF-LTP is induced independ-
ently of activation of any ionotropic glutamate recep-
tors (Nicoll and Malenka, 1995). However, subsequent
studies identified roles for kainate receptors (KARs)
(Bortolotto et al., 1999; Contractor et al., 2001) in
MF-LTP induction. Prior to this, metabotropic gluta-
mate receptors (mGluRs) were also shown to be
involved in the induction of MF-LTP (Ito and
Sugiyama, 1991; Bashir et al., 1993). These findings
have not, however, met with universal acceptance.
With respect to mGluRs, there are reports that antago-
nists for these receptors, including the prototypic
mGluR antagonist, a-methyl-4-carboxyphenylglycine
(MCPG) (Bashir et al., 1993), either block the induc-
tion of MF-LTP (Ito and Sugiyama, 1991; Bashir
et al., 1993; Yeckel et al., 1999; Itoh et al., 2001;
Thompson et al., 2005; Nistico et al., 2011) or have
no effect (Manzoni et al., 1994; Hsia et al., 1995; Mel-
lor and Nicoll, 2001; Barnes et al., 2010). Regarding
KARs, there is general agreement that these can act as
triggers for LTP (Bortolotto et al., 1999; Contractor
et al., 2001; Schmitz et al., 2003; Pinheiro et al.,
2007; Catches et al., 2012). However, there is disagree-
ment regarding whether the KAR involved contains the
GluK1 subunit (Bortolotto et al., 1999; Lauri et al.,
2001; More et al., 2004; Nistico et al., 2011) or not
(Contractor et al., 2001; Breustedt and Schmitz,
2004).
Most previous studies concerning the role of
mGluRs and all previous studies concerning the role
of KARs in MF-LTP have been performed in brain
slices. Differences in the experimental conditions
employed may partly explain the differing results
obtained. Indeed, there are several incidences where
differences in the experimental conditions can dramat-
ically affect the outcome of the experiments. For
example, it was found that increasing the extracellular
Ca21 concentration from 2 to 4 mM negated the
need for the synaptic activation of GluK1 KARs for
the induction of MF-LTP (Lauri et al., 2003). Fur-
thermore, increasing tetanization strength or artifi-
cially increasing depolarization levels can result in the
induction of LTP through mechanisms independent
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of KAR activation (Schmitz et al., 2003; Pinheiro et al., 2007).
Recently, it was found that the role of GluK1-containing KARs is
dependent on the slice orientation, with antagonists showing effi-
cacy in parasagittal but not transverse preparations (Sherwood
et al., 2012). These dramatic differences led us to investigate the
role of mGluRs and KARs at the hippocampal MF synapse in vivo.
In this study, we observed a slowly developing MF-LTP, in
both pentobarbitone- and urethane-anesthetized rats, that was
independent of the synaptic activation of NMDARs. This
form of LTP, which closely resembled that described previously
in vivo (Derrick and Martinez, 1994), was insensitive to a
range of mGluR and KAR antagonists delivered by intrahippo-
campal (i.h.) injection. Furthermore, a combination of either
an mGlu1 ((S)-(1)-a-amino-4-carboxy-2-methylbenzeneacetic
acid; LY367385), or an mGlu5, (2-methyl-6-(phenylethynyl)-




zine-2,3-dicarboxylic acid; UBP161) was also ineffective. How-
ever, blockade of both group I mGluR subtypes, using either
MCPG or a combination of LY367385 and MPEP, together
with blockade of GluK1-containing KARs, using either ACET
or UBP161, significantly reduced or completely prevented the
induction of MF-LTP. These findings suggest that the activa-
tion of either mGlu1 receptors or mGlu5 receptors or GluK1-
containing KARs during tetanization is sufficient to induce
MF-LTP in vivo, such that all three receptors need to be antag-
onized for the process to be blocked. This suggests that all
three receptor subtypes are activated synaptically during high-
frequency transmission and play interchangeable roles in the
induction of MF-LTP in vivo.
MATERIALS AND METHODS
This study was performed in accordance with The Animals
(Scientific Procedures) Act (1986) and with the approval of the
University of Bristol Ethics Committee.
Electrophysiology
Adult male Wistar rats (300–400 g; Charles River Laborato-
ries, United Kingdom) were anesthetized with a sodium pento-
barbitone solution (60 mg/kg, i.p.; Sigma-Aldrich, United
Kingdom). The jugular vein was then cannulated with PE10
tubing and anesthesia was maintained by continual intravenous
perfusion of sodium pentobarbitone (20 mg/kg/h). Surgical
anesthesia was confirmed by the absence of the pedal withdrawal
and corneal reflexes. Urethane was used to anesthetize animals
in a subset of experiments (1.4 g/kg, i.p.; 25% urethane). The
anesthetized rat was placed in a stereotaxic frame and its temper-
ature was maintained at 37 C with a homeothermic blanket.
Stimulating and recording electrodes were then positioned in
the MF pathway. A concentric bipolar tungsten electrode was
positioned in the granule cell layer of the dentate gyrus accord-
ing to the co-ordinates from bregma (anterior–posterior [AP],
23.6; mediolateral (ML), 22.0). A further concentric bipolar
tungsten electrode was positioned in area CA3 of the hippo-
campus (AP, 23.0; ML, 22.3) (Fig. 1(i)). While using it to
stimulate antidromically, the electrode in area CA3 was lowered
until characteristic spikes from the granule cells, with a peak
onset of 2–3 ms, were observed from the electrode in the den-
tate gyrus (Derrick and Martinez, 1994). The depth of the
electrode in the dentate gyrus was then adjusted until charac-
teristic MF field excitatory postsynaptic potentials (fEPSPs)
were achieved following orthodromic stimulation (Fig. 1(iii)).
These fEPSPs had an onset latency of 2–3 ms and a peak of
7–10 ms (Derrick and Martinez, 1994). (2S,20R,30R)-2-
(20,30-dicarboxycyclopropyl)glycine) (DCG-IV) was applied at
the end of all MF experiments to confirm the absence of asso-
ciational/commissural pathway contamination (Kamiya et al.,
1996; Yeckel et al., 1999; Hagena and Manahan-Vaughan,
2010; Sherwood et al., 2012). The experiments where DCG-
IV did not depress the fEPSP slope by at least 70% were
excluded from any analysis, for the concern of contamination
from another form of LTP.
The stimulating electrode positioned in the dentate gyrus
was connected to a constant current isolated stimulator (Quest
scientific, Digitimer), which in turn was attached to a personal
computer via a digital analogue converter (National Instru-
ments, BNC2090). Stimulation intensity was set manually on
an isolated stimulator, with a single, biphasic stimulus with the
duration of 0.2 ms and intensity initially at 10 lA. The
responses were obtained through the recording electrode,
amplified with a differential amplifier (Warner Instruments,
PP-304) and were filtered at 0.1 Hz–1 kHz. In brief, 50 Hz
noise was minimized with a Hum Bug (Quest Scientific, Digi-
timer). The recordings were processed and stored via an inter-
face digital/analogue converter board (M-series, v1.01) to a
personal computer (Windows XP) running Win LTP (Ander-
son and Collingridge, 2007).
The stimulation intensity was set to evoke fEPSPs of 50%
of the maximal response and a baseline frequency of 0.033 Hz
was used throughout. The initial fEPSP slope (12.5–87.5% of
the rising phase) was used as a measure of response magnitude.
After obtaining a stable baseline, of at least 15 min, antagonists
were applied over a 10 min period by intrahippocampal injec-
tion. To achieve this, a guide cannula was attached to the
recording electrode. A 33 gauge cannula was inserted through
the guide, with the end positioned 1 mm adjacent to the
recording electrode tip. The cannula was connected to PE10
tubing, drug solutions were drawn into the tubing, as measured
with a 5 lL microsyringe (Hamilton). In most experiments, 20
min after the i.h. injection, ketamine was injected (10 mg/kg,
i.v.). Two trains of tetanization were then applied (100 Hz, 1 s,
30 s intertrain interval) 10 min later.
At the completion of every experiment, high-intensity cur-
rent was passed through both the stimulating and the recording
electrodes. The resulting lesions allowed the determination of
the electrode positions. The animal was then sacrificed by
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cervical dislocation and the brain was removed. The cerebellum
and frontal cortex were removed and the brain was mounted
for coronal slicing. The mounted tissue was bathed in physio-
logical saline (0.9%). Slices (thickness, 300 lm) were cut,
removed, and stored in physiological saline to avoid swelling or
dehydration. The photographs of the lesions were taken, from
unstained tissue, with a universal serial bus Microcapture cam-
era and software (Fig. 1(ii)). The positioning of electrodes was
FIGURE 1. Mossy fiber LTP in vivo. (i) Schematic illustration
of stimulating (upper) and recording electrode (lower) positions in
the coronal plane of the hippocampus with corresponding stereo-
taxic co-ordinates (adapted from Paxinos and Watson’s Atlas, The
Rat Brain in Stereotaxic Coordinates, 6th ed., 2006, Elsevier.). (ii)
Examples of electrically induced lesions illustrating stimulating (a)
and recording (b) electrode positions in the hippocampus from a
MF-LTP experiment, (iii) fEPSP elicited by stimulating from den-
tate gyrus (a) to CA3 (b); Spike evoked by antidromic stimulation
of the granule cells in CA3 (b) and recorded in dentate gyrus (a),
(iv) fEPSP recordings remain stable for >140 min (n5 5). Vehicle
injection (i.h.) has no effect on fEPSP slope. Insets are representa-
tive fEPSPs at the indicated time points from individual experi-
ments. [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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used as another criterion to confirm that fEPSPs were originating
from the MFs. The experiments in which the stimulating elec-
trode was not in dentate gyrus or the recording electrode was not
approximately in stratum lucidum of CA3 were discarded.
Drugs
Stock solutions for all drugs applied by i.h. injection were
diluted in physiological saline (0.9%). ACET, D-(2)-2-amino-5-
phosphonopentanoic acid (D-AP5), DCG-IV, LY367385,
MCPG, and MPEP were all sourced from Tocris, Untied King-
dom; sodium pentobarbitone and urethane were obtained from
Sigma-Aldrich, United Kingdom; UBP161 was synthesized in-
house as reported previously (Irvine et al., 2012). The com-
pounds, ACET (0.1 nmol), D-AP5 (1 nmol), UBP161 (1 nmol),
LY367385 (0.3 and 1 nmol), MPEP (0.3 and 1 nmol), MCPG
(1, 5 and 50 nmol), and interleaved vehicle controls, were
injected in a 2 lL volume i.h. over a 10 min period. DCG-IV
(0.01 nmol) was injected in a 1 lL volume i.h. over a 10 min
period, 90 min after tetanization. The concentrations of mGlu
agonist or antagonists were similar to those used by others
(Manahan-Vaughan and Reymann, 1997; Manahan-Vaughan
et al., 1998; Naie and Manahan-Vaughan, 2004, 2005).
Data Analysis
All data were presented as the fEPSP slope normalized to
baseline, with each point representing the average of four suc-
cessive fEPSPs recorded at 30 s intervals. Pooled data were pre-
sented as the mean of the normalized fEPSPs of individual
experiments6 the standard error of the mean.
One-way ANOVAs, with Dunnet’s post hoc tests, were used
to compare the magnitude of MF-LTP (at 90 min after tetani-
zation) in rats treated with each antagonist versus the inter-
leaved vehicle-treated control group. For the experiments
investigating the NMDAR dependence of CA1 LTP, the mag-
nitude of LTP 60 min after tetanization was compared, in the
presence or absence of D-AP5, with a t-test.
RESULTS
Properties of MF-LTP In Vivo
In the presence of the NMDAR antagonist, D-AP5 (i.h.),
high-frequency stimulation (HFS) (2 3 100 Hz for 1 s, 30 s
intertrain interval) within the dentate gyrus, resulted in a slow-
onset LTP recorded in area CA3 (1526 12% of baseline, 90
min after tetanization; n5 4; Fig. 2A). The effectiveness of the
D-AP5 treatment was evaluated in area CA1. In this region,
HFS (3 3 100 Hz, 1 s, 240 s intertrain interval) induced a
rapid-onset LTP (1486 6%; n5 4, gray symbols) that was sig-
nificantly inhibited by the NMDAR antagonist (1126 7%;
n5 4, black symbols; t-test, P< 0.05; Fig. 2B).
A slow-onset LTP was also observed in area CA3 in rats in
which the NMDAR antagonist ketamine (Anis et al., 1983)
was injected (10 mg/kg, i.v.) 10 min before delivering HFS
(1556 5%, n5 11; P> 0.05; Fig. 2C). These data demon-
strate that HFS can induce an NMDAR-independent LTP in
area CA3 after stimulation within the dentate gyrus. Although
this LTP differed from MF-LTP as observed in slice prepara-
tions by the absence of short-term potentiation (STP) (Con-
tractor et al., 2001; Lauri et al., 2001), it closely resembled
that observed previously in anesthetized rats (Derrick and Mar-
tinez, 1994; Thompson et al., 2005; Gomez-Palacio and Esco-
bar, 2012). In all subsequent experiments, ketamine (10 mg/
kg, i.v.) was applied prior to the delivery of HFS.
We wondered if the absence of STP might be owing to the
use of a barbiturate anesthetic. However, a similar slow onset
LTP was observed when anesthesia was induced with urethane
(1826 16%, n5 5; Fig. 2D).
MF fEPSPs Are Sensitive to Group II mGluR
Agonism
The application of a Group II mGluR agonist, such as
DCG-IV, is often used to define mossy fiber projections
(Kamiya et al., 1996; Mellor and Nicoll, 2001; Gomez-Palacio
and Escobar, 2012; Hagena and Manahan-Vaughan, 2010).
Here, MF fEPSPs were found to be sensitive to DCG-IV (0.01
nmol, i.h.) (Fig. 2E). DCG-IV reduced the fEPSP slope rela-
tive to preinjection levels (reduction, 916 3%; n5 11;
P< 0.05; Fig. 2F).
Inhibition of Either KARs or mGluRs Alone
Does Not Affect MF-LTP
We started by testing two KAR antagonists, ACET and
UBP161, which have been shown to be potent at GluK1-
containing KARs (Dargan et al., 2009; Irvine et al., 2012). We
applied the concentrations that we considered would substan-
tially block GluK1-containing KARs in vivo, based on their
established potencies as GluK1 antagonists and the dilution
factor estimated from the DCG-IV experiments. However, we
were still able to induce MF-LTP following i.h. injections of
either of these compounds: ACET (0.1 nmol; 1596 7%;
n5 5; Fig. 3A) or UBP161 (1 nmol; 1376 12%; n5 5; Fig.
3B).
Next, we tested three mGluR antagonists, MCPG (Eaton
et al., 1993), MPEP (Gasparini et al., 1999), and LY367385
(Clarke et al., 1997), using the concentrations that we esti-
mated should effectively engage their targets based on their
known potencies. For each antagonist we used two different
doses. Invariably, we were also able to induce MF-LTP: MCPG
(5 nmol: 1266 7%; n5 5; Fig. 3C; 50 nmol: 1376 11%;
n5 5), MPEP (0.3 nmol: 1356 6%; n5 4; 1 nmol:
1686 21%; n5 4; Fig. 3D), LY367385 (0.3 nmol:
1596 22%; n5 3; 1 nmol: 1376 11%; n5 4; Fig. 3E). We
also observed LTP when we applied a combination of MPEP
plus LY367385 (1 nmol of each: 1556 6%; n5 4; Fig. 3F).
In all cases, there was a significant LTP that was not signifi-
cantly different to that induced in the vehicle-treated control
groups (P> 0.05).
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Effects of the Combined Inhibition of mGluRs
and KARs on MF-LTP
Next, we tested the effects of inhibiting either mGlu1 or
mGlu5 together with the inhibition of KARs. With all
combinations, HFS again elicited a significant MF-LTP that was
not significantly different to that induced in vehicle-injected
controls (0.1 nmol ACET plus 1 nmol MPEP; 1626 15%;
n5 4; 1 nmol UBP1611 1 nmol MPEP: 1426 10%; n5 4;
0.1 nmol ACET1 1 nmol LY367385: 1456 14%; n5 4; 1
nmol UBP1611 1 nmol LY367385: 1666 8%; n5 4;
P> 0.05; Fig. 4).
Finally, we tested the effects of inhibiting mGlu1 and mGlu5
together with KARs. First, we tested the effects of ACET along
with three doses of MCPG and the combination of MPEP and
LY367385. In all cases, LTP was significantly smaller compared
FIGURE 2. The properties of MF-LTP in vivo. (A) MF-LTP
can be induced in the presence of the NMDAR antagonist, D-AP5
(1 nmol, i.h.; n5 4). (B) CA1 LTP can be induced by three trains
of tetanization (3 3 100 stimuli at 100 Hz, 240 s intertrain inter-
val; n5 4). The application of D-AP5 (1 nmol, i.h.) 30 min before
tetani blocks CA1 LTP (n5 4, darker symbol). (C) MF-LTP
recorded in the presence of ketamine (10 mg/kg, i.v., 10 min
before tetani). (D) Slow-onset MF-LTP is also induced with ure-
thane anesthesia (n5 4). (E, F) A single example (E) and pooled
data (F) (n5 11) showing the effects of DCG-IV (0.01 nmol, i.h.),
tested 90 min after the induction of MF-LTP. Unless otherwise
stated, in this and subsequent figures, gray symbols represent vehi-
cle controls, and black symbols represent the drug treatment indi-
cated. In this figure and Figures 3 and 4, traces are the average of
4 consecutive fEPSPs responses obtained during baseline (1) and
90 min following (2) the delivery of two tetani (arrows).
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to vehicle or eliminated (0.001 nmol ACET1 1 nmol MCPG:
1226 9; n5 5; 0.1 nmol ACET1 5 nmol MCPG: 956 14%;
n5 4; P< 0.05; 0.1 nmol ACET1 50 nmol MCPG:
1046 15; n5 4; 0.1 nmol ACET1 1 nmol MPEP1 1 nmol
LY367385: 1076 6%; n5 4; P< 0.05; Figs. 5A,B). Similar
effects were observed with UBP161 (1 nmol UBP1611 50
nmol MCPG: 1376 16%; n5 5; P< 0.05; 1 nmol
UBP1611 1 nmol MPEP1 1 nmol LY367385: 1206 5%;
n5 5; P< 0.05; Figs. 5C,D). These data suggest that HFS of
MFs results in the activation of all of the three receptors studied
(mGlu1, mGlu5, and KAR); such that both Group I mGluRs
plus GluK1-KARs need to be antagonized to prevent MF-LTP
in vivo. These data are summarised in Figure 6.
DISCUSSION
In this study, we have examined the sensitivity of MF-LTP
in vivo to a variety of mGluR and KAR antagonists. Our
principal finding is that the activation of either one of the
Group I mGluRs (mGlu1 or mGlu5) or a KAR is sufficient
for the induction of MF-LTP in anesthetized rats. Thus, it
was necessary to block both mGlu1 and mGlu5 as well as
KARs to prevent the induction of MF-LTP. These observa-
tions show that glutamate receptors are required for the
induction of MF-LTP but that KAR and mGluRs can play
interchangeable roles.
FIGURE 3. KAR or mGluR antagonists applied alone do not
affect MF-LTP. (A, B) The GluK1 antagonists ACET (A: 0.1 nmol,
i.h.; n5 5) or UBP161 (B, 1 nmol, i.h.; n5 5) fail to block MF-
LTP. (C–F) The broad spectrum mGluR antagonist MCPG (C, 5
nmol, i.h.; n5 5), the mGlu5 receptor antagonist, MPEP (D, 1
nmol, i.h.; n5 4), the mGlu1 receptor antagonist LY367385 (E, 1
nmol, i.h.; n5 4) or the combination of LY367385 and MPEP (F,
1 and 1 nmol, i.h.; n5 4) does not block MF-LTP.
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MF-LTP In Vivo
The LTP that we recorded in this study did not resemble
MF-LTP as observed in hippocampal slices in that we
observed a slowly developing potentiation. In these respects,
the LTP that we observed closely resembled MF-LTP as ini-
tially described in anesthetized rats by Derrick et al. (1991).
Despite the differences from the extensive number of studies
performed in slices, we are confident that we were studying
MF-LTP because (i) we only observed this LTP when the
electrodes were correctly positioned to stimulate and record
from the MF pathway, (ii) this LTP was resistant to antago-
nism of NMDA receptors, and (iii) the recorded fEPSPs
were reduced by DCG-IV. We do not know the reason for
the absence of STP, but it is unlikely to be attributed to the
use of any one specific anesthetic as we observed a similar
profile when using either pentobarbitone or urethane. A sim-
ilar profile has also been observed with isoflurane (Ballesteros
et al., 2012). Other possibilities include the differences in
temperature between in vitro (typically between 22 and 31
C: Pinheiro et al., 2007; Nistico et al., 2011) and in vivo
(37 C) preparations, and the differences in divalent cation
concentrations.
Glutamate Receptors and the Induction
of MF-LTP In Vivo
We tested three different mGluR antagonists. MCPG is the
prototypic mGluR antagonist (Eaton et al., 1993) that inhibits
some (mGlu1, mGlu2, mGlu3, mGlu5, and mGlu8) but not
all mGluR subtypes (Schoepp et al., 1999). MPEP is a potent
and selective mGlu5 receptor antagonist (Gasparini et al.,
1999), with weak activity at NMDA receptors in high concen-
trations (O’Leary et al., 2000). LY367385 is a fairly selective
mGlu1 receptor antagonist (Clarke et al., 1997). Our finding
that neither LY367385 nor MPEP alone or in combination sig-
nificantly affected LTP suggests that the inhibition of Group I
mGluRs alone is not sufficient to block LTP. Consistent with
this conclusion, MCPG also failed to prevent the induction of
MF-LTP. These observations contrast with the report that a
different Group I mGluR antagonist, AIDA, can prevent the
induction of MF-LTP in vivo (Thompson et al., 2005). It is
possible, however, that the differences in the experimental con-
ditions in vivo can affect the ability of Group I mGluR antago-
nists to affect MF-LTP. In this study, it is unlikely that the
antagonists failed to reach the concentrations effective for
antagonizing Group I mGluRs as they were highly effective
FIGURE 4. Combined application of KAR antagonists with either mGlu1 or mGlu5 recep-
tor antagonists does not affect MF-LTP. (A–D) Intrahippocampal injection of ACET and
MPEP (A: 0.1 and 1 nmol, i.h.; n5 4), UBP161 and MPEP (B: 1 and 1 nmol, i.h.; n5 4),
ACET and LY367385 (C: 0.1 and 1 nmol, i.h.; n5 4) or UBP161 and LY367385 (D: 1 and 1
nmol, i.h.; n5 4) does not affect MF-LTP.
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when applied in combination with KAR antagonists. We con-
clude, therefore, that MF-LTP can be induced in vivo despite
substantial inhibition of Group I mGluRs.
We tested two structurally different KAR antagonists. ACET
is a highly potent antagonist at GluK1-containing KARs (Dar-
gan et al., 2009) and has weaker activity at some GluK3-
containing KARs (Perrais et al., 2009). UBP161 is a more
recently described KAR antagonist that is not related structur-
ally to ACET (Irvine et al., 2012). It is less potent, but more
selective, than ACET as a GluK1 antagonist, displaying over a
100-fold selectivity at GluK1 relative to GluK2 and GluK3
(Irvine et al., 2012). It is also an NMDA receptor antagonist
(Irvine et al., 2012). Our finding that neither ACET nor
UBP161 affected LTP suggests that the inhibition of GluK1-
containing KARs alone is not sufficient to prevent LTP in vivo.
Again, their effectiveness in combination with mGluR antago-
nists argues against the possibility that we did not achieve a
sufficiently high concentration to antagonize KARs.
The finding that the combinations of mGluR and KAR
antagonists were effective at blocking MF-LTP argues for an
involvement of both ionotropic and metabotropic receptors in
this process. As we observed similar effects using either MCPG
or a combination of MPEP and LY367385 and similar effects
using ACET or UBP161 it is unlikely that the sites of action
are some undefined target. Rather, we would argue that these
results strongly suggest the need to antagonize both Group I
mGluRs and KARs to prevent the induction of LTP. Interest-
ingly, it was necessary to block both mGlu1 and mGlu5, sug-
gesting that these play interchangeable roles. Surprisingly, the
observation that it was additionally necessary to block KARs
suggests that mGluRs and KARs play interchangeable roles
too. This is an unusual scenario where metabotropic and iono-
tropic glutamate receptors can substitute for one another in a
physiological function.
Comparison with Studies in Hippocampal Slices
How do our findings in vivo compare with those in hippo-
campal slices? In making this comparison, it is important to
note that there are striking differences in the physiology and
pharmacology of MF responses and LTP profiles between para-
sagittal and transverse slices (Sherwood et al., 2012).
With respect to synaptic waveforms, the responses that we
have recorded are similar to those obtained from parasagittal
FIGURE 5. Combined application of KAR antagonists with mGlu1 and mGlu5 receptor
antagonists inhibits MF-LTP. (A–D) Intrahippocampal injection of ACET and MCPG (A: 0.1
and 5 nmol, i.h.; n5 4), ACET and MPEP and LY367385 (B: 0.1, 1, and 1 nmol, i.h.; n5 4)
UBP161 and MCPG (C: 1 and 5 nmol, i.h.; n5 5) or UBP161 and MPEP and LY367385 (D:
1, 1 and 1 nmol, i.h.; n5 5) blocks the induction of MF-LTP.
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slices but quite distinct from those observed in transverse slices,
which tend to be much smaller, faster, and irregular in appear-
ance. In terms of mGluRs, our findings that neither MPEP nor
LY367385 blocked LTP when applied alone are consistent with
our previous studies in parasagittal brain slices using the same
antagonists (Nistico et al., 2011). However, in contrast to this
study, we observed complete block of MF-LTP when we used
either MCPG (Bashir et al., 1993; Nistico et al, 2011) or a
combination of MPEP and LY367385 (Nistico et al., 2011) in
parasagittal slices. The lack of effect of MCPG, that we have
observed in this study, resembles the situation in experiments
that have used transverse hippocampal slices (Manzoni et al.,
1994; Hsia et al., 1995). The effects of DCG-IV are similar to
those reported by us (Sherwood et al., 2012) and others
(Kamiya et al., 1996) using transverse slices but differ from
our observations in parasagittal slices where responses were
insensitive to this group II mGluR agonist.
With respect to KARs, the finding that ACET when applied
alone had no effect on LTP is consistent with our observations
in transverse slices but contrasts with our findings in parasagit-
tal slices, where ACET fully blocked LTP (Dargan et al., 2009;
Sherwood et al., 2012). Indeed, when using parasagittal brain
slices, we have observed the block of LTP by six structurally
distinct KAR antagonists over a 20,000-fold concentration
range (Jane et al., 2009).
In summary, the nature of the MF-LTP observed in this
study neither matches that seen by us or others in either trans-
verse or parasagittal slices, but has some features in common
with both. It is most similar to our previous work in parasagit-
tal slices, where we found that either mGlu1 and mGlu5
antagonism or GluK1 antagonism was sufficient to block the
induction of MF-LTP (Nistico et al., 2011). The principal dif-
ference being that here we found that mGlu1 and mGlu5 plus
GluK1 antagonism is required.
The Mechanism of Induction of MF-LTP In Vivo
Based on our present findings, we would suggest that both
mGluRs and KARs are involved in MF-LTP in vivo. Our
results are consistent with a scenario where any of the three
receptors studied, mGlu1, mGlu5, or GluK1-KARs, is suffi-
cient to induce MF-LTP and hence the need to antagonize all
three. The major difference between the present observations
and our previous work in vitro is the need to block KARs and
Group I mGluRs as opposed to either type alone. One poten-
tial explanation for this difference could be at the level of
Ca21 stores. We have shown that in parasagittal slices, the
release of Ca21 from ryanodine-sensitive stores is required for
MF-LTP (Lauri et al., 2003). We speculated that Group I
mGluRs, which couple to phospholipase C, generate IP3 and
FIGURE 6. Summary of the effects of KAR and group 1 mGluR antagonists on MF-LTP
magnitude. (A) No significant effects of KAR or mGluR antagonists on MF-LTP when applied
alone. (B) No significant effects of KAR antagonists when applied with an mGlu1 or with an
mGlu5 receptor antagonist. But the combination of KAR and mGlu1 and mGlu5 receptor
antagonists did significantly reduce MF-LTP (*P< 0.05). The control from all interleaved
experiments is shown in both (A) and (B) for the convenience of the reader. The numbers in
parenthesis are the drug doses in nmol.
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KARs lead to Ca2 entry, which then act in concert to release
Ca2 from stores. The present results could be explained by a
similar mechanism, but where either IP3, generated by the acti-
vation of mGlu1 and/or mGlu5 receptors, or Ca21 entry,
resulting from the activation of KARs, is sufficient to release
Ca21 from stores. This might occur if stores are in a more sen-
sitized state in vivo, possibly as a result of a more complete fill-
ing of the stores under resting conditions. Further work will be
required to test this hypothesis directly.
ACKNOWLEDGMENT
J. L. W. was an MRC scholar.
REFERENCES
Anderson WW, Collingridge GL. 2007. Capabilities of the WinLTP
data acquisition program extending beyond basic LTP experimental
functions. J Neurosci Methods 162:346–356.
Anis NA, Berry SC, Burton NR, Lodge D, 1983. The dissociative
anaesthetics, ketamine and phencyclidine, selectively reduce excita-
tion of central mammalian neurones by N-methyl-aspartate. Br J
Pharmacol 79:565–575.
Ballesteros KA, Sikorski A, Orfila JE, Martinez JJ. 2012. Effects of
inhaled anesthetic isoflurane on long-term potentiation of ca3
pyramidal cell afferents in vivo. Int J Gen Med 5:935–942.
Barnes SJ, Opitz T, Merkens M, Kelly T, von der Brelie C, Krueppel
R, Beck H, 2010. Stable mossy fiber long-term potentiation
requires calcium influx at the granule cell soma, protein synthesis,
and microtubule-dependent axonal transport. J Neurosci 30:
12996–13004.
Bashir ZI, Bortolotto ZA, Davies CH, Berretta N, Irving AJ, Seal AJ,
Henley JM, Jane DE, Watkins JC, Collingridge GL. 1993. Induc-
tion of LTP in the hippocampus needs synaptic activation of gluta-
mate metabotropic receptors. Nature 363:347–350.
Bliss TV, Collingridge GL. 1993. A synaptic model of memory:
Long-term potentiation in the hippocampus. Nature 361:31–39.
Bliss TV, Collingridge GL. 2013. Expression of NMDA receptor-
dependent LTP in the hippocampus: Bridging the divide. Mol
Brain 6:.
Bortolotto ZA, Clarke VR, Delany CM, Parry MC, Smolders I,
Vignes M, Ho KH, Miu P, Brinton BT, Fantaske R, Ogden A,
Gates M, Ornstein PL, Lodge D, Bleakman D, Collingridge GL.
1999. Kainate receptors are involved in synaptic plasticity. Nature
402:297–301.
Breustedt J, Schmitz D, 2004. Assessing the role of gluk5 and gluk6
at hippocampal mossy fiber synapses. J Neurosci 24:10093–10098.
Catches JS, Xu J, Contractor A, 2012. Genetic ablation of the GluK4
kainate receptor subunit causes anxiolytic and antidepressant-like
behavior in mice. Behav Brain Res 228:406–414.
Clark BP, Baker SR, Goldsworth J, Harris JR, Kingston AE. 1997. (1)-2-
Methyl-4-carboxyphenylglycine (ly367385) selectively antagonises
metabotropic glutamate mGluR1 receptors. Bioorg Med Chem Lett 7:
2777–2780.
Contractor A, Swanson G, Heinemann SF. 2001. Kainate receptors
are involved in short-and long-term plasticity at mossy fiber synap-
ses in the hippocampus. Neuron 29:209–216.
Dargan SL, Clarke VR, Alushin GM, Sherwood JL, Nistico R,
Bortolotto ZA, Ogden AM, Bleakman D, Doherty AJ, Lodge D,
Mayer ML, Fitzjohn SM, Jane DE, Collingridge GL. 2009. ACET
is a highly potent and specific kainate receptor antagonist:
Characterisation and effects on hippocampal mossy fibre function.
Neuropharmacology 56:121–130.
Derrick BE, Martinez JJL. 1994. Frequency-dependent associative
long-term potentiation at the hippocampal mossy fiber-ca3 syn-
apse. Proc Natl Acad Sci USA 91:10290–10294.
Derrick BE, Weinberger SB, Martinez JJL. 1991. Opioid receptors are
involved in an NMDA receptor-independent mechanism of LTP
induction at hippocampal mossy fiber-ca3 synapses. Brain Res Bull
27:219–223.
Eaton SA, Jane DE, Jones PL, Porter RH, Pook PC, Sunter DC,
Udvarhelyi PM, Roberts PJ, Salt TE, Watkins JC. 1993. Competi-
tive antagonism at metabotropic glutamate receptors by (S)-4-car-
boxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine.
Eur J Pharmacol 244:195–197.
Gasparini F, Lingenh€ohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic
I, Biollaz M, Allgeier H, Heckendorn R, Urwylerm S, Varney MA,
Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Velic¸elebi
G, Kuhn R, 1999. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) a
potent, selective and systemically active mGlu5 receptor antagonist.
Neuropharmacology 38:1493–1503.
Gomez-Palacio SA, Escobar ML. 2012. In vivo BDNF modulation of
hippocampal mossy fiber plasticity induced by high frequency
stimulation. Hippocampus 22:1–8.
Hagena H, Manahan-Vaughan D, 2010. Frequency facilitation at
mossy fiber–ca3 synapses of freely behaving rats contributes to the
induction of persistent LTD via an Adenosine-a1 Receptor-regu-
lated mechanism. Cereb Cortex 20:1121–1130.
Harris EW, Cotman CW. 1986. Long-term potentiation of guinea pig
mossy fiber responses is not blocked by N-methyl D-aspartate
antagonists. Neurosci Lett 70:132–137.
Hsia A, Salin P, Castillo P, Aiba A, Abeliovich A, Tonegawa S, Nicoll
RA. 1995. Evidence against a role for metabotropic glutamate
receptors in mossy fiber LTP: The use of mutant mice and phar-
macological antagonists. Neuropharmacology 34:1567–1572.
Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield
CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB,
Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnar
E, Monaghan DT, Jane DE. 2012. Piperazine-2,3-dicarboxylic acid
derivatives as dual antagonists of NMDA and GluK1-containing
kainate receptors. J Med Chem 55:327–341.
Ito I, Sugiyama H, 1991. Roles of glutamate receptors in long-term
potentiation at hippocampal mossy fiber synapses. Neuroreport 2:
333–336.
Itoh S, Ito K-I, Fujii S, Kaneko K, Kato K, Mikoshiba K, Kato H,
2001. Neuronal plasticity in hippocampal mossy fiber–ca3 synapses
of mice lacking the inositol-1, 4, 5-trisphosphate type 1 receptor.
Brain Res 901:237–246.
Jane DE, Lodge D, Collingridge GL. 2009. Kainate receptors: Phar-
macology, function and therapeutic potential. Neuropharmacology
56:90–113.
Kamiya H, Shinozaki H, Yamamoto C, 1996. Activation of metabo-
tropic glutamate receptor type 2/3 suppresses transmission at rat
hippocampal mossy fibre synapses. J Physiol 493:447–455.
Lauri SE, Bortolotto ZA, Bleakman D, Ornstein PL, Lodge D, Isaac
JT, Collingridge GL. 2001. A critical role of a facilitatory presyn-
aptic kainate receptor in mossy fiber LTP. Neuron 32:697–709.
Lauri SE, Bortolotto ZA, Nistico R, Bleakman D, Ornstein PL,
Lodge D, Isaac JT, Collingridge GL. 2003. A role for ca21 stores
in kainate receptor-dependent synaptic facilitation and LTP at
mossy fiber synapses in the hippocampus. Neuron 39:327–341.
Manahan-Vaughan D, Reymann KG. 1997. Group 1 metabotropic
glutamate receptors contribute to slow-onset potentiation in the rat
ca1 region in vivo. Neuropharmacology 36:1533–1538.
Manahan-Vaughan D, Braunewell KH, Reymann KG. 1998. Subtype-
specific involvement of metabotropic glutamate receptors in two
forms of long-term potentiation in the dentate gyrus of freely mov-
ing rats. Neuroscience 86:709–721.
1416 WALLIS ET AL.
Hippocampus
Manzoni OJ, Weisskopf MG, Nicoll RA. 1994. MCPG antagonizes
metabotropic glutamate receptors but not long-term potentiation
in the hippocampus. Eur J Neurosci 6:1050–1054.
Mellor J, Nicoll RA. 2001. Hippocampal mossy fiber LTP is inde-
pendent of postsynaptic calcium. Nat Neurosci 4:125–126.
More JC, Nistico R, Dolman NP, Clarke VR, Alt AJ, Ogden AM,
Buelens FP, Troop HM, Kelland EE, Pilato F, Bleakman D,
Bortolotto ZA, Collingridge GL, Jane DE. 2004. Characterisation
of ubp296: A novel, potent and selective kainate receptor antago-
nist. Neuropharmacology 47:46–64.
Naie K, Manahan-Vaughan D, 2004. Regulation by metabotropic gluta-
mate receptor 5 of LTP in the dentate gyrus of freely moving rats: Rele-
vance for learning and memory formation. Cereb Cortex 14:189–198.
Naie K, Manahan-Vaughan D, 2005. Pharmacological antagonism of
metabotropic glutamate receptor 1 regulates long-term potentiation
and spatial reference memory in the dentate gyrus of freely moving
rats via N-methyl-D-aspartate and metabotropic glutamate
receptor-dependent mechanisms. Eur J Neurosci 21:411–421.
Nicoll RA, Malenka RC. 1995. Contrasting properties of two forms of
long-term potentiation in the hippocampus. Nature 377:115–118.
Nicoll RA, Schmitz D, 2005. Synaptic plasticity at hippocampal
mossy fibre synapses. Nat Rev Neurosci 6:863–876.
Nistico R, Dargan SL, Amici M, Collingridge GL, Bortolotto ZA.
2011. Synergistic interactions between kainate and mGlu receptors
regulate bouton ca21 signalling and mossy fibre LTP. Sci Rep 1:
1–9.
O’Leary DM, Movsesyan V, Vicini S, Faden AI. 2000. Selective
mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or
glutamate-mediated neuronal toxicity through actions that reflect
NMDA receptor antagonism. Br J Pharmacol 131:1429–1437.
Paxinos G, Watson C. 2006. The Rat Brain in Stereotaxic Coordi-
nates, 6th ed. San Diego, Elsevier.
Perrais D, Pinheiro PS, Jane DE, Mulle C, 2009. Antagonism of
recombinant and native GluK3-containing kainate receptors. Neu-
ropharmacology 56:131–140.
Pinheiro PS, Perrais D, Coussen F, Barhanin J, Bettler B, Mann JR,
Malva JO, Heinemann SF, Mulle C, 2007. GluR7 is an essential
subunit of presynaptic kainate autoreceptors at hippocampal mossy
fiber synapses. Proc Natl Acad Sci 104:12181–12186.
Schmitz D, Mellor J, Breustedt J, Nicoll RA. 2003. Presynaptic kai-
nate receptors impart an associative property to hippocampal
mossy fiber long-term potentiation. Nat Neurosci 6:1058–1063.
Schoepp DD, Jane DE, Monn JA. 1999. Pharmacological agents act-
ing at subtypes of metabotropic glutamate receptors. Neurophar-
macology 38:1431–1476.
Sherwood JL, Amici M, Dargan SL, Culley GR, Fitzjohn SM, Jane
DE, Collingridge GL, Lodge D, Bortolotto ZA. 2012. Differences
in kainate receptor involvement in hippocampal mossy fibre long-
term potentiation depending on slice orientation. Neurochem Int
61:482–489.
Thompson KJ, Mata ML, Orfila JE, Barea-Rodriguez EJ, Martinez JL.
2005. Metabotropic glutamate receptor antagonist AIDA blocks induc-
tion of mossy fiber-ca3 LTP in vivo. J Neurophysiol 93:2668–2673.
Yeckel MF, Kapur A, Johnston D, 1999. Multiple forms of LTP in
hippocampal ca3 neurons use a common postsynaptic mechanism.
Nat Neurosci 2:625–633.
ROLES FOR GLUTAMATE RECEPTORS IN MF-LTP INDUCTION 1417
Hippocampus
